Free Trial

Johnson & Johnson (JNJ) Stock Forecast & Price Target

Johnson & Johnson logo
$148.10 +1.07 (+0.73%)
As of 01/21/2025 03:59 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Johnson & Johnson - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
8
Buy
6

Based on 14 Wall Street analysts who have issued ratings for Johnson & Johnson in the last 12 months, the stock has a consensus rating of "Hold." Out of the 14 analysts, 8 have given a hold rating, and 6 have given a buy rating for JNJ.

Consensus Price Target

$173.27
16.99% Upside
According to the 14 analysts' twelve-month price targets for Johnson & Johnson, the average price target is $173.27. The highest price target for JNJ is $215.00, while the lowest price target for JNJ is $150.00. The average price target represents a forecasted upside of 16.99% from the current price of $148.10.
Get the Latest News and Ratings for JNJ and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Johnson & Johnson and its competitors.

Sign Up

JNJ Analyst Ratings Over Time

TypeCurrent Forecast
1/23/24 to 1/22/25
1 Month Ago
12/24/23 to 12/23/24
3 Months Ago
10/25/23 to 10/24/24
1 Year Ago
1/23/23 to 1/23/24
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
6 Buy rating(s)
7 Buy rating(s)
7 Buy rating(s)
5 Buy rating(s)
Hold
8 Hold rating(s)
7 Hold rating(s)
6 Hold rating(s)
8 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$173.27$174.73$175.93$167.80
Forecasted Upside16.99% Upside20.28% Upside7.49% Upside5.03% Upside
Consensus Rating
Hold
Moderate Buy
Moderate Buy
Hold

JNJ Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

JNJ Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Johnson & Johnson Stock vs. The Competition

TypeJohnson & JohnsonMedical CompaniesS&P 500
Consensus Rating Score
2.46
2.82
2.52
Consensus RatingHoldModerate BuyModerate Buy
Predicted Upside17.96% Upside24,755.71% Upside11.35% Upside
News Sentiment Rating
Positive News

See Recent JNJ News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
1/21/2025Barclays
3 of 5 stars
 Lower TargetEqual Weight ➝ Equal Weight$160.00 ➝ $159.00+7.65%
1/17/2025Bank of America
3 of 5 stars
Tim Anderson
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetNeutral ➝ Neutral$166.00 ➝ $160.00+8.65%
12/11/2024Citigroup
3 of 5 stars
 Lower TargetBuy ➝ Buy$185.00 ➝ $175.00+19.18%
11/15/2024Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
A. Hammond
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$190.00+25.12%
11/6/2024Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$156.00 ➝ $162.00+2.40%
10/16/2024Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight ➝ Overweight$215.00 ➝ $215.00+30.70%
10/16/2024Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetEqual Weight ➝ Equal Weight$163.00 ➝ $166.00+0.91%
10/16/2024Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$178.00 ➝ $181.00+10.28%
10/16/2024Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetEqual Weight ➝ Equal Weight$169.00 ➝ $175.00+6.62%
7/23/2024Daiwa America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
N. Nakagiri
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
7/23/2024Daiwa Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Neutral$160.00 ➝ $150.00-2.75%
7/19/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral ➝ Neutral$160.00 ➝ $155.00+0.27%
7/18/2024Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$161.00 ➝ $171.00+9.10%
7/18/2024TD Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$195.00 ➝ $185.00+18.03%
7/18/2024TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$195.00 ➝ $185.00+18.38%
4/18/2024HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy$169.00 ➝ $170.00+17.43%
1/3/2024Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$172.00 ➝ $175.00+8.93%
12/1/2023UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Buy$167.00 ➝ $180.00+16.39%
8/4/2023Atlantic Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$167.00 ➝ $170.00-0.42%
7/21/2023JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral$175.00 ➝ $180.00+5.75%
7/21/2023Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$165.00 ➝ $175.00+3.92%
7/21/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral$170.00 ➝ $175.00+3.92%
2/6/2023Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$55.00 ➝ $52.00-68.17%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 02:49 AM ET.


Should I Buy Johnson & Johnson Stock? JNJ Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, January 12, 2025. Please send any questions or comments about these Johnson & Johnson pros and cons to contact@marketbeat.com.

Johnson & Johnson
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Johnson & Johnson:

  • Johnson & Johnson reported earnings per share (EPS) of $2.42 for the latest quarter, exceeding the consensus estimate of $2.21, indicating strong financial performance and effective management.
  • The company has a solid net margin of 19.14%, which reflects its ability to convert revenue into profit efficiently, making it an attractive option for investors seeking profitability.
  • With a current stock price of $146.19, Johnson & Johnson's shares have shown resilience, trading above its twelve-month low of $142.75, suggesting stability in the stock's performance.
  • Johnson & Johnson has a robust dividend yield of 3.44%, with a quarterly dividend of $1.24 per share, appealing to income-focused investors looking for regular returns.
  • The company has a strong return on equity of 35.45%, indicating effective use of shareholders' equity to generate profits, which is a positive sign for potential investors.

Johnson & Johnson
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Johnson & Johnson for these reasons:

  • Johnson & Johnson's EPS decreased from $2.66 in the same period last year to $2.42, which may raise concerns about declining profitability and growth potential.
  • The stock has been downgraded from a "strong-buy" to a "buy" rating by analysts, indicating a potential shift in market sentiment and caution among investors.
  • Analysts have varied price targets, with some reducing their expectations, such as Citigroup lowering its price objective from $185.00 to $175.00, which may signal uncertainty about future performance.
  • Despite a strong market cap of $351.97 billion, the company's P/E ratio of 21.16 suggests that the stock may be overvalued compared to its earnings, which could deter value investors.
  • Institutional ownership stands at 69.55%, which may indicate that the stock is heavily held by large investors, potentially limiting price appreciation for retail investors.

JNJ Forecast - Frequently Asked Questions

According to the research reports of 14 Wall Street equities research analysts, the average twelve-month stock price forecast for Johnson & Johnson is $173.27, with a high forecast of $215.00 and a low forecast of $150.00.

14 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Johnson & Johnson in the last twelve months. There are currently 8 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" JNJ shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in JNJ, but not buy additional shares or sell existing shares.

According to analysts, Johnson & Johnson's stock has a predicted upside of 16.99% based on their 12-month stock forecasts.

Johnson & Johnson has been rated by research analysts at Bank of America, Barclays, Citigroup, Guggenheim, and Wolfe Research in the past 90 days.

Analysts like Johnson & Johnson less than other "medical" companies. The consensus rating for Johnson & Johnson is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how JNJ compares to other companies.


This page (NYSE:JNJ) was last updated on 1/22/2025 by MarketBeat.com Staff
From Our Partners